These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 29563974)

  • 1. The effectiveness of lixisenatide as an add on therapy to basal insulin in diabetic type 2 patients previously treated with different insulin regimes: a multi-center observational study.
    Božek T; Bilić-Ćurčić I; Berković MC; Gradišer M; Kurir TT; Majanović SK; Marušić S
    Diabetol Metab Syndr; 2018; 10():16. PubMed ID: 29563974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Achieving postprandial glucose control with lixisenatide improves glycemic control in patients with type 2 diabetes on basal insulin: a post-hoc analysis of pooled data.
    Davidson JA; Stager W; Paranjape S; Berria R; Leiter LA
    Clin Diabetes Endocrinol; 2020; 6():2. PubMed ID: 31956422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensification of Basal Insulin Therapy with Lixisenatide in Patients with Type 2 Diabetes in a Real-World Setting: The BASAL-LIXI Study.
    Bellido D; Abellán P; Ruiz Palomar JM; Álvarez Sintes R; Nubiolae A; Bellido V; Romero G;
    Curr Ther Res Clin Exp; 2018; 89():37-42. PubMed ID: 30455779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis.
    Charbonnel B; Bertolini M; Tinahones FJ; Domingo MP; Davies M
    J Diabetes Complications; 2014; 28(6):880-6. PubMed ID: 25130920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lixisenatide is effective and safe as add-on treatment to basal insulin in Asian individuals with type 2 diabetes and different body mass indices: a pooled analysis of data from the GetGoal Studies.
    Feng W; Wang W; Meng R; Wu G; Zhang M; Zhang X; Yin H; Zhu D
    BMJ Open Diabetes Res Care; 2021 Aug; 9(1):. PubMed ID: 34452904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Effectiveness and Safety of Lixisenatide as Add-On to Oral Antidiabetic Drugs as Part of Routine Clinical Practice in Bulgaria: LIXODAR Study.
    Temelkova N; Vladeva S; Delchev A; Ivanova K; Gerasimova-Zheleva Y; Kuneva T; Pehlivanova V; Popivanov P
    Diabetes Ther; 2019 Jun; 10(3):981-993. PubMed ID: 30919317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L).
    Riddle MC; Aronson R; Home P; Marre M; Niemoeller E; Miossec P; Ping L; Ye J; Rosenstock J
    Diabetes Care; 2013 Sep; 36(9):2489-96. PubMed ID: 23628617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of lixisenatide in the treatment of Type 2 diabetes mellitus: a review of Phase III clinical data.
    Raccah D
    Expert Rev Endocrinol Metab; 2013 Mar; 8(2):105-121. PubMed ID: 30736171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Real-World, Observational Study of the Initiation, Use, and Effectiveness of Basal-Bolus or Premixed Insulin in Japanese People with Type 2 Diabetes.
    Miyoshi H; Baxter M; Kimura T; Hattori M; Morimoto Y; Marinkovich D; Tamiwa M; Hirose T
    Diabetes Ther; 2021 May; 12(5):1341-1357. PubMed ID: 33730337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Premixed vs basal-bolus insulin regimen in Type 2 diabetes: comparison of clinical outcomes from randomized controlled trials and real-world data.
    Anyanwagu U; Mamza J; Gordon J; Donnelly R; Idris I
    Diabet Med; 2017 Dec; 34(12):1728-1736. PubMed ID: 28945928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the efficacy and safety of lixisenatide add-on treatment to basal insulin therapy among T2DM patients with different body mass indices from GetGoal trials.
    Eto K; Naito Y; Seino Y
    Diabetol Metab Syndr; 2015; 7():106. PubMed ID: 26594250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing glycemic control: lixisenatide and basal insulin in combination therapy for the treatment of Type 2 diabetes mellitus.
    Aronson R
    Expert Rev Clin Pharmacol; 2013 Nov; 6(6):603-12. PubMed ID: 24147558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lixisenatide as add-on treatment among patients with different β-cell function levels as assessed by HOMA-β index.
    Bonadonna RC; Blonde L; Antsiferov M; Berria R; Gourdy P; Hatunic M; Mohan V; Horowitz M
    Diabetes Metab Res Rev; 2017 Sep; 33(6):. PubMed ID: 28303626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indirect comparison of lixisenatide versus neutral protamine Hagedorn insulin as add-on to metformin and sulphonylurea in patients with type 2 diabetes mellitus.
    Fournier M; Germe M; Theobald K; Scholz GH; Lehmacher W
    Ger Med Sci; 2014; 12():Doc14. PubMed ID: 25332702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (<50 years) obese patients with type 2 diabetes mellitus.
    Van Gaal L; Souhami E; Zhou T; Aronson R
    J Clin Transl Endocrinol; 2014 Jun; 1(2):31-37. PubMed ID: 29159080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from The Health Improvement Network (THIN) Database in the United Kingdom.
    Feher M; Vega-Hernandez G; Mocevic E; Buysse B; Myland M; Power GS; Nystrup Husemoen LL; Kim J; Witte DR
    Diabetes Ther; 2017 Apr; 8(2):417-431. PubMed ID: 28281244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes.
    Ericsson Å; Glah D; Lorenzi M; Jansen JP; Fridhammar A
    PLoS One; 2018; 13(2):e0191953. PubMed ID: 29408938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lixisenatide Improves Glycemic Control in Asian Type 2 Diabetic Patients Inadequately Controlled With Oral Antidiabetic Drugs: An Individual Patient Data Meta-Analysis.
    Shu H; Gu LN; Men LC; Lu JM
    Diabetes Ther; 2016 Dec; 7(4):777-792. PubMed ID: 27796905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved Glycemic Control with Insulin Glargine 300 U/mL (Toujeo
    Wiesli P; Schories M
    Diabetes Ther; 2018 Dec; 9(6):2325-2334. PubMed ID: 30302721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Clinical Effectiveness and Tolerability of Hydroxychloroquine 400 Mg in Uncontrolled Type 2 Diabetes Subjects who are not Willing to Initiate Insulin Therapy (HYQ-Real-World Study).
    Gupta A
    Curr Diabetes Rev; 2019; 15(6):510-519. PubMed ID: 31713476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.